Catheter Precision (VTAK) Restructuring Costs (2022)

Catheter Precision's (VTAK) quarterly Restructuring Costs came in at -$3.2 million in Q4 2022, down 451.0% on a QoQ basis from $900000.0 in Q3 2022.

Catheter Precision (VTAK) Restructuring Costs (2022) Analysis & Trends

Catheter Precision (VTAK) has 1 years of Restructuring Costs data on file, last reported at -$3.2 million in Q4 2022.

On a quarterly basis, Restructuring Costs changed N/A year-over-year to -$3.2 million in Q4 2022; TTM through Sep 2023 was -$2.3 million, a N/A change from a year earlier, with the FY2022 full-year figure at $910000.0, changed N/A from the prior year.
Restructuring Costs for Q4 2022 stood at -$3.2 million, down from $900000.0 in the prior quarter.
Over the last five years, Restructuring Costs for VTAK reached as high as $3.5 million in Q2 2022 and fell as low as -$3.2 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Catheter Precision	0.80	-811,999.20	390,000.00

Download Data